Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
ConditionInterstitial Lung Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBastiaan Driehuys
About this trial
The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function. Specifically, three forms of 129Xe MRI contrast will be the investigators focus - 1) imaging of the 129Xe ventilation distribution, 2) imaging the alveolar microstructure via the 129Xe apparent diffusion coefficient (ADC), and 3) imaging 129Xe that dissolves in the pulmonary blood and tissues upon inhalation. Such imaging of 129Xe gas transfer is expected to be uniquely sensitive to pathologies affecting gas exchange (fibrosis, emphysema, pulmonary hypertension) and provide new insights regarding the normal resting heterogeneity of pulmonary gas exchange.
Eligibility criteria
Qualifiers
Subject has no diagnosed pulmonary conditions
Subject has not smoked in the previous 5 years.
Smoking history, if any, is less than or equal to 5 pack-years.
Subject has a diagnosis of pulmonary dysfunction made by a physician
Disqualifiers
Subject is less than 18 years old
MRI is contraindicated based on responses to MRI screening questionaire
Subject is pregnant or lactating
Respiratory illness of a bacterial or viral etiology within 30 days of MRI
Trial design
Treatments tested in this trial
- Hyperpolarized 129Xenon Gas
Treatment groups
No treatment groups listed
Sponsors and collaborators
Bastiaan Driehuys
Lead sponsor
Duke University
Sponsor institution
Source ClinicalTrials.gov